Recovery of tissue function following administration of B cells to injured tissue
AssigneeActX, Inc.
InventorsMark C. Poznansky, Traci T. Goodchild, Mark T. Ungs, Nicholas A. F. Chronos, Nadine Weich
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to systems and methods of enhancing recovery of function of injured tissue through administration of a composition comprising a relatively pure populations of B lymphocyte cells in a pharmaceutically acceptable carrier to the injured tissue. Kits are provided to aid in purification of B cells from heterogeneous mixtures of cells and administration of B cells to injured tissue.
Claims11
A method of treating injured ischemic tissue in an animal or a human comprising administering an amount of a composition comprising a relatively pure population of autologous isolated B cells in a pharmaceutically acceptable carrier to the animal or the human with the injured ischemic tissue, wherein the amount is effective to treat the injured ischemic tissue, wherein the relatively pure population of the isolated B cells is prepared by a method comprising substantially removing stem cells from a heterogeneous population of cells containing the stem cells and the B cells to create the relatively pure population of the isolated B cells.
A method for treating injured ischemic tissue in an animal or a human comprising:
- obtaining a sample containing B cells from the animal or the human with the injured ischemic tissue;
- purifying the sample to produce a relatively pure population of isolated B cells, wherein the relatively pure population of the isolated B cells is prepared by a method comprising substantially removing stem cells from the sample containing a heterogeneous population of cells containing the stem cells and the B cells to create the relatively pure population of the isolated B cells;
- combining the relatively pure population of the isolated B cells with a pharmaceutically acceptable carrier to produce a composition;
- and
- administering the composition to the animal or the human with the injured ischemic tissue in an amount effective to treat the injured ischemic tissue in the animal or the human.
Dependencies are inferred from the claim text.